Polyrizon's Naloxone Formulation Shows Superior Nasal Deposition Rates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PLRZ?
Polyrizon announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma's Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies. Key Findings: Polyrizon's advanced nasal formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate, a highly vascularized region that may support rapid systemic absorption and potentially enhance the onset and bioavailability of intranasally administered drugs. In comparison, the reference commercial product delivered only 79.6% to the same nasal cavity area. Polyrizon's formulation also showed significantly lower deposition in the lower turbinate region, potentially reducing posterior runoff and unintended drainage toward the nasopharynx, which may support improved dosing consistency and systemic delivery efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLRZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLRZ
About PLRZ
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Polyrizon Launches New Allergy Product NASARIX™
- Branding Progress: Early in 2026, Polyrizon Ltd. completed the rebranding of its lead intranasal allergy product from PL-14 to NASARIX™, including trademark screening in the U.S. and European markets, marking a significant step toward potential commercialization for the Israeli biotech firm.
- Market Demand Analysis: The global market for allergic rhinitis treatments is projected to reach USD 13.08 billion by 2025 and grow to USD 18.81 billion by 2035, with a CAGR of 3.7%, indicating strong demand for intranasal therapies and non-sedating alternatives, highlighting substantial commercial potential in this sector.
- Technological Innovation Advantage: NASARIX™ utilizes Polyrizon's Capture and Contain™ hydrogel technology to create a bio-adhesive barrier that effectively traps allergens before they reach sensitive nasal tissue, offering a drug-free preventive protection, particularly suitable for high-exposure environments.
- Clinical Trial Outlook: Polyrizon initiated a key human factors and usability study on January 22, 2026, with clinical trials expected to commence in Q3 2026; if human trial results confirm efficacy and safety, it will pave the way for market introduction of the product.
See More
Polyrizon Launches New Allergy Product NASARIX™
- Branding Progress: Early in 2026, Polyrizon Ltd. completed the rebranding of its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™, marking a significant step towards potential commercialization and enhancing market recognition for the Israeli biotech firm.
- Substantial Market Potential: The global market for allergic rhinitis treatments is projected to grow from USD 13.08 billion in 2025 to USD 18.81 billion by 2035, with a CAGR of 3.7%, providing Polyrizon with vast market opportunities, particularly against the backdrop of rising demand for non-drug therapies.
- Innovative Technical Advantage: NASARIX™ utilizes Capture and Contain™ hydrogel technology to create a bio-adhesive barrier that effectively traps allergens, with preclinical data showing superior allergen-blocking capabilities compared to standard products, which could attract users seeking natural preventive protection if human trial results confirm efficacy.
- Clinical Trial Preparations: Polyrizon initiated a key human factors and usability study on January 22, 2026, with clinical trials expected to commence in Q3 2026, a progress that not only strengthens the regulatory foundation of the product but may also expedite the FDA approval process, allowing for quicker market entry.
See More
Polyrizon Signs Agreement to Acquire Stake in Arrow Aviation
- Acquisition Agreement: Polyrizon announced the signing of a memorandum of understanding to acquire a 51% stake in global private aviation firm Arrow Aviation for NIS 18 million ($5.8 million), which is expected to significantly enhance the company's market position.
- Market Potential: Arrow Aviation specializes in private flight services, including medical evacuations and special needs transport, with the private aviation market projected to grow to $41.38 billion by 2030, allowing Polyrizon to enter this rapidly expanding sector through the acquisition.
- Financial Strength: CEO Tomer Izraeli stated that this acquisition will leverage Polyrizon's strong financial position to diversify its business further and enhance its competitiveness in the aviation market.
- Strategic Implications: By acquiring a high-growth potential company, Polyrizon not only expands its business scope but also positions itself favorably for future market competition, seizing growth opportunities in the industry.
See More
Polyrizon to Acquire 51% Stake in Arrow Aviation
- Strategic Diversification: Polyrizon Ltd. has signed a non-binding MOU to acquire a 51% stake in Arrow Aviation Ltd. for NIS 18 million (approximately $5.8 million), marking a strategic entry into the high-growth private aviation sector.
- Financial Performance: Arrow Aviation generates approximately $19 million in annual revenue and $3 million in adjusted EBITDA, providing various services including medical evacuations and special-needs transport, enhancing Polyrizon's market potential in aviation.
- Debt Restructuring: As part of the transaction, Arrow Aviation's existing shareholders will forgive outstanding loans in exchange for Polyrizon's convertible notes, allowing Arrow Aviation to achieve a debt-free status post-closing, further optimizing its financial structure.
- Market Outlook: Industry forecasts project the private aviation market to reach $41.38 billion by 2030, aligning Polyrizon's acquisition strategy with its exploration of revenue-generating opportunities in high-growth sectors, which is expected to yield significant revenue growth for the company.
See More
Polyrizon Signs MOU to Acquire 51% Stake in Arrow Aviation
- Strategic Expansion: Polyrizon has signed a non-binding MOU with Arrow Aviation to acquire a 51% stake through a cash investment of NIS 18 million (approximately $5.8 million), marking a strategic move into the high-growth private aviation sector.
- Financial Background: Arrow Aviation generates approximately $19 million in annual revenue with an adjusted EBITDA of $3 million, providing high-quality VIP flight services that cater to a diverse clientele, showcasing its competitive position in the market.
- Market Potential: This acquisition will enable Polyrizon to enter the rapidly growing private aviation market, with expectations to drive future revenue growth and market share expansion by integrating Arrow Aviation's resources and customer base.
- Investment Intent: Through this investment, Polyrizon not only strengthens its business footprint in the aviation sector but also demonstrates its commitment to the high-end service market, aiming to leverage the growth potential of private aviation services to achieve long-term strategic objectives.
See More
Polyrizon Signs MOU with Arrow Aviation for Strategic Acquisition
- Strategic Acquisition Plan: Polyrizon intends to acquire a 51% stake in Arrow Aviation through a cash investment of NIS 18 million (approximately $5.8 million), marking a strategic expansion into the high-growth private aviation market, which is projected to reach $41.38 billion by 2030.
- Arrow Aviation Overview: With annual revenues of approximately $19 million and adjusted EBITDA of about $3 million, Arrow Aviation is a leading provider of private aviation services, offering high-standard VIP flights that cater to diverse needs, thereby enhancing Polyrizon's competitive edge in the market.
- Debt Forgiveness Arrangement: As part of the transaction, existing shareholders of Arrow Aviation will forgive outstanding debts in exchange for convertible notes issued by Polyrizon, enabling Arrow Aviation to operate debt-free post-closing, thus improving its financial health.
- Future Growth Potential: The MOU includes mutual call and put options on the remaining 49% of Arrow Aviation's shares, based on agreed valuation multiples tied to financial metrics, potentially allowing Polyrizon to fully acquire Arrow Aviation in the future, further strengthening its market position in the aviation sector.
See More
Polyrizon Launches New Allergy Product NASARIX™
- Branding Progress: Early in 2026, Polyrizon Ltd. completed the rebranding of its lead intranasal allergy product from PL-14 to NASARIX™, including trademark screening in the U.S. and European markets, marking a significant step toward potential commercialization for the Israeli biotech firm.
- Market Demand Analysis: The global market for allergic rhinitis treatments is projected to reach USD 13.08 billion by 2025 and grow to USD 18.81 billion by 2035, with a CAGR of 3.7%, indicating strong demand for intranasal therapies and non-sedating alternatives, highlighting substantial commercial potential in this sector.
- Technological Innovation Advantage: NASARIX™ utilizes Polyrizon's Capture and Contain™ hydrogel technology to create a bio-adhesive barrier that effectively traps allergens before they reach sensitive nasal tissue, offering a drug-free preventive protection, particularly suitable for high-exposure environments.
- Clinical Trial Outlook: Polyrizon initiated a key human factors and usability study on January 22, 2026, with clinical trials expected to commence in Q3 2026; if human trial results confirm efficacy and safety, it will pave the way for market introduction of the product.
See More
Polyrizon Launches New Allergy Product NASARIX™
- Branding Progress: Early in 2026, Polyrizon Ltd. completed the rebranding of its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™, marking a significant step towards potential commercialization and enhancing market recognition for the Israeli biotech firm.
- Substantial Market Potential: The global market for allergic rhinitis treatments is projected to grow from USD 13.08 billion in 2025 to USD 18.81 billion by 2035, with a CAGR of 3.7%, providing Polyrizon with vast market opportunities, particularly against the backdrop of rising demand for non-drug therapies.
- Innovative Technical Advantage: NASARIX™ utilizes Capture and Contain™ hydrogel technology to create a bio-adhesive barrier that effectively traps allergens, with preclinical data showing superior allergen-blocking capabilities compared to standard products, which could attract users seeking natural preventive protection if human trial results confirm efficacy.
- Clinical Trial Preparations: Polyrizon initiated a key human factors and usability study on January 22, 2026, with clinical trials expected to commence in Q3 2026, a progress that not only strengthens the regulatory foundation of the product but may also expedite the FDA approval process, allowing for quicker market entry.
See More
Polyrizon Signs Agreement to Acquire Stake in Arrow Aviation
- Acquisition Agreement: Polyrizon announced the signing of a memorandum of understanding to acquire a 51% stake in global private aviation firm Arrow Aviation for NIS 18 million ($5.8 million), which is expected to significantly enhance the company's market position.
- Market Potential: Arrow Aviation specializes in private flight services, including medical evacuations and special needs transport, with the private aviation market projected to grow to $41.38 billion by 2030, allowing Polyrizon to enter this rapidly expanding sector through the acquisition.
- Financial Strength: CEO Tomer Izraeli stated that this acquisition will leverage Polyrizon's strong financial position to diversify its business further and enhance its competitiveness in the aviation market.
- Strategic Implications: By acquiring a high-growth potential company, Polyrizon not only expands its business scope but also positions itself favorably for future market competition, seizing growth opportunities in the industry.
See More
Polyrizon to Acquire 51% Stake in Arrow Aviation
- Strategic Diversification: Polyrizon Ltd. has signed a non-binding MOU to acquire a 51% stake in Arrow Aviation Ltd. for NIS 18 million (approximately $5.8 million), marking a strategic entry into the high-growth private aviation sector.
- Financial Performance: Arrow Aviation generates approximately $19 million in annual revenue and $3 million in adjusted EBITDA, providing various services including medical evacuations and special-needs transport, enhancing Polyrizon's market potential in aviation.
- Debt Restructuring: As part of the transaction, Arrow Aviation's existing shareholders will forgive outstanding loans in exchange for Polyrizon's convertible notes, allowing Arrow Aviation to achieve a debt-free status post-closing, further optimizing its financial structure.
- Market Outlook: Industry forecasts project the private aviation market to reach $41.38 billion by 2030, aligning Polyrizon's acquisition strategy with its exploration of revenue-generating opportunities in high-growth sectors, which is expected to yield significant revenue growth for the company.
See More
Polyrizon Signs MOU to Acquire 51% Stake in Arrow Aviation
- Strategic Expansion: Polyrizon has signed a non-binding MOU with Arrow Aviation to acquire a 51% stake through a cash investment of NIS 18 million (approximately $5.8 million), marking a strategic move into the high-growth private aviation sector.
- Financial Background: Arrow Aviation generates approximately $19 million in annual revenue with an adjusted EBITDA of $3 million, providing high-quality VIP flight services that cater to a diverse clientele, showcasing its competitive position in the market.
- Market Potential: This acquisition will enable Polyrizon to enter the rapidly growing private aviation market, with expectations to drive future revenue growth and market share expansion by integrating Arrow Aviation's resources and customer base.
- Investment Intent: Through this investment, Polyrizon not only strengthens its business footprint in the aviation sector but also demonstrates its commitment to the high-end service market, aiming to leverage the growth potential of private aviation services to achieve long-term strategic objectives.
See More
Polyrizon Signs MOU with Arrow Aviation for Strategic Acquisition
- Strategic Acquisition Plan: Polyrizon intends to acquire a 51% stake in Arrow Aviation through a cash investment of NIS 18 million (approximately $5.8 million), marking a strategic expansion into the high-growth private aviation market, which is projected to reach $41.38 billion by 2030.
- Arrow Aviation Overview: With annual revenues of approximately $19 million and adjusted EBITDA of about $3 million, Arrow Aviation is a leading provider of private aviation services, offering high-standard VIP flights that cater to diverse needs, thereby enhancing Polyrizon's competitive edge in the market.
- Debt Forgiveness Arrangement: As part of the transaction, existing shareholders of Arrow Aviation will forgive outstanding debts in exchange for convertible notes issued by Polyrizon, enabling Arrow Aviation to operate debt-free post-closing, thus improving its financial health.
- Future Growth Potential: The MOU includes mutual call and put options on the remaining 49% of Arrow Aviation's shares, based on agreed valuation multiples tied to financial metrics, potentially allowing Polyrizon to fully acquire Arrow Aviation in the future, further strengthening its market position in the aviation sector.
See More
